Betaloc I.V. Injection
Last Updated on eMC 13-Mar-2017 View document | AstraZeneca UK Limited Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 13-Mar-2017 and displayed until Current
Reasons for adding or updating:
- Change to section 2 - use in children/adolescents
- Change to section 6 - date of revision
- Improved presentation of PIL
Updated on 10-Sep-2014 and displayed until 13-Mar-2017
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 5 - how to store
- Change to section 6 - date of revision
- Change to section 2 - what you need to know - contraindications
Updated on 24-Dec-2013 and displayed until 10-Sep-2014
Reasons for adding or updating:
- Change to section 2 - what you need to know - contraindications
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 28-Feb-2011 and displayed until 24-Dec-2013
Reasons for adding or updating:
- Change to warnings or special precautions for use
Updated on 05-Jan-2010 and displayed until 28-Feb-2011
Reasons for adding or updating:
- Change of manufacturer
Updated on 09-Jun-2008 and displayed until 05-Jan-2010
Reasons for adding or updating:
- Change to side-effects
- Change due to user-testing of patient information
Updated on 03-May-2007 and displayed until 09-Jun-2008
Reasons for adding or updating:
- Improved Electronic Presentation
- Change to warnings or special precautions for use
- Change of contra-indications
- Change to instructions about overdose
- Change to storage instructions
- Change to side-effects
- Change to drug interactions
- Change from BAN to rINN
Updated on 12-Aug-2005 and displayed until 03-May-2007
Reasons for adding or updating:
- Improved Electronic Presentation
Updated on 04-Sep-2002 and displayed until 12-Aug-2005
Reasons for adding or updating:
- New PIL for eMC ie a PIL for an existing product but new to the eMC
AstraZeneca UK Limited
Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU
+44 (0)1582 838 000
+44 (0)1582 838 003
+44 (0)1582 836 000
0800 783 0033
+44 (0)1582 837 837
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue